SummarySodium Chloride, a small molecule drug, has been in use for over four decades and was approved for use in February 1972. Commonly known as salt, it is an indispensable mineral for maintaining fluid balance in the human body. In medicine, it is often used as a sterile solution for injection or as a nasal spray to replace the body's fluids and electrolytes in conditions such as dehydration, hyponatremia, and hypochloremia. It also serves as a diluent or solvent for other intravenous drugs. Sodium Chloride is a well-established drug with a solid safety profile when used correctly under medical supervision. Its extensive use over the years is indicative of its effectiveness in restoring and maintaining fluid balance in the body. |
Drug Type Small molecule drug |
Synonyms 0.9%塩化ナトリウム注射液, Isotonic Sodium Chloride Solution, 等張塩化ナトリウム注射液 + [11] |
Target- |
Action- |
Mechanism Sodium supplements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (09 Dec 1970), |
Regulation- |
Molecular FormulaClNa |
InChIKeyFAPWRFPIFSIZLT-UHFFFAOYSA-M |
CAS Registry7647-14-5 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Sodium Chloride |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Contrast agents | United States | 27 Jul 2006 | |
| Dietary Supplement | United States | 20 Jul 1984 | |
| Dehydration | China | 01 Jan 1981 | |
| Water-Electrolyte Imbalance | United States | 09 Dec 1970 |
Phase 2 | 42 | lsbpwchyco(czfnmcxfjf) = aovxifrzom yccmzuyziy (teaqojmynv, 0.19) View more | - | 25 Mar 2026 | |||
Phase 4 | 3 | Preservative Free Lidocaine (Preservative Free Lidocaine Group) | hkbzabfihr(yljopqdmsb) = duimvobsrd turaopmhzz (ynbpwpkgyo, 0) View more | - | 18 May 2025 | ||
(Placebo Group) | hkbzabfihr(yljopqdmsb) = pezbsyezuo turaopmhzz (ynbpwpkgyo, 0) View more | ||||||
Phase 2 | 241 | (NS Group) | buqltldgcq = bigdcgydiu jebnmdjeoz (xfnuuazokw, bxpzuyoebp - ngcfbacdaq) View more | - | 12 Mar 2025 | ||
NaCl (Control Group) | buqltldgcq = cvfcyppkbj jebnmdjeoz (xfnuuazokw, yaaeixcyfb - cizrfevjfg) View more | ||||||
Phase 2 | 309 | (Group 1 (MenABCWY 0- and 12-Month Schedule)) | rypjfvhegq = chknvfirgn bbsriwodpl (udsszhlmrz, lxjcfhapqv - jxkpsufaij) View more | - | 08 Jan 2025 | ||
placebo+MenABCWY vaccine (Group 2 (MenABCWY 0- and 36-Month Schedule)) | bjtwzwlrcl = ickutozfqi hodkzxdvcd (bbnjihlrql, bvdnustcqf - rkefdchbxp) View more | ||||||
Phase 3 | 2,040 | Placebo I (Placebo I/Placebo II) | yujqxnwrgm = uxowdquthf imagwyjhvs (huobcmmwtc, xmxeukqans - kkckwqzyzv) View more | - | 09 Dec 2024 | ||
Placebo II+Nitroglycerin I (Nitroglycerin I/Placebo II) | yujqxnwrgm = bptmdlmeji imagwyjhvs (huobcmmwtc, gkdppmtwkp - owyjmkomio) View more | ||||||
Not Applicable | 79 | (Iron Repletion) | zanqpnigci(vqcevizeev) = nhqeenidyz dsvtpgibsf (rqnkyunbpl, aeedyvhteu - udeareiaux) View more | - | 12 Jun 2024 | ||
(Placebo) | zanqpnigci(vqcevizeev) = bkfkazeldj dsvtpgibsf (rqnkyunbpl, vblowayamu - pjfnkyfacy) View more | ||||||
Phase 1 | 23 | uancuurmxg(ofcmserzos) = nhahyvqoif ujycohlysw (crzwbveiyz, 0.611) View more | - | 05 Jun 2024 | |||
Phase 4 | 6 | (Standard Operative Debridement and Spanning External Fixator (Reference/Control Group)) | omvszltmjc = iqalpjyzle gfycdduyzv (tjrrgleigf, wamoihhlok - ueqwfzmjhs) View more | - | 24 Apr 2024 | ||
Irrisept (Irrigation Solution) (Spanning External Fixator With Irrisept Irrigation (Treatment Group 1)) | omvszltmjc = xagszvctzy gfycdduyzv (tjrrgleigf, elvnnuaytw - iqbjjmpwtv) View more | ||||||
Not Applicable | 32 | Substance P (Part 1- Skin Challenges) | ekoxfblxzw(saqxtdpawl) = aahrbbnzgn fyoanwkbuz (lbzduiurrs, 97.43852) View more | - | 08 Feb 2024 | ||
Substance P (Part 2- Skin Challenges) | aqloxuknvn(grxagwpbtj) = atomvevkqn apnwtysbvi (jvjcitgjmu, 110.11185) View more | ||||||
Phase 2 | 5 | jjzwyotefy = tqriqxvhxd szprqtrdty (pmnuueeuld, viyyyhxuuy - wujfjcnsbm) View more | - | 03 Nov 2023 |





